TOP > 外国特許検索 > IgG-BINDING PEPTIDE, AND SPECIFIC MODIFICATION OF ANTIBODY WITH SAID PEPTIDE

IgG-BINDING PEPTIDE, AND SPECIFIC MODIFICATION OF ANTIBODY WITH SAID PEPTIDE

Foreign code F190009749
File No. S2017-0814-C0
Posted date 2019年5月7日
Country 世界知的所有権機関(WIPO)
International application number 2018JP019287
International publication number WO 2018230257
Date of international filing 平成30年5月18日(2018.5.18)
Date of international publication 平成30年12月20日(2018.12.20)
Priority data
  • 特願2017-118735 (2017.6.16) JP
Title IgG-BINDING PEPTIDE, AND SPECIFIC MODIFICATION OF ANTIBODY WITH SAID PEPTIDE
Abstract The present invention addresses the problem of providing: a method for modifying an antibody in a specific and simple manner; and others. The present invention relates to: an IgG-binding peptide; an IgG-binding peptide modified with a crosslinking agent; a complex of an IgG-binding peptide modified with the crosslinking agent and IgG; a method for producing the complex; and others.
Outline of related art and contending technology BACKGROUND ART
Antibodies, various types of research in the prior art, in the development, detection of target molecules and often used, and the detection reagent to a surface of the industry as a diagnostic, and are extremely important. In addition, the antibody, the specificity for its target molecule, as a medicament for the treatment of disease are noted.
For adding a function of the chemical modifications, such as alkaline phosphatase or peroxidase (HRP) (AP) (Non-Patent Document 1-2) such as enzymes, radioactive isotopes as well as for the addition of a chelate compound and a iodinated (Non-Patent Document 3), a low molecular weight compound such as biotin modifications have been made by the (non-patent document 4) has. These modifications, the amino group of lysine to the main and the thiol group of cysteine, and the activated carboxyl group and the via, but are specific for a functional group, not a site-specific, such as a modification to the antigen binding site of the activity of the antibody is a problem. Further, detection sensitivity or to enhance the therapeutic effect, and increase the number of ligand is introduced, the amino acid residues of the modified antibody with the increase in the physical properties of structure is changed, the activity of the antibody is decreased or causes non-specific binding, the detection sensitivity and specificity of the treatment effect and leading to a decrease.
In order to overcome such a problem, a specific functional group is introduced into the site-specific antibody is used, is performed to modify the antibody. For example, non-natural amino acid cysteine (Non-Patent Document 5-7) or free (non-patent document 8-9) is introduced, at a particular site can be introduced by the modification of a genetically engineered, modified at a specific site has become possible. Transglutaminase (TG) using addition, naturally or artificially introduced into the antibody specific glutamine to the modified target is reported (Non-Patent Document 10-11), and the structure of the compound is introduced into the, a glutamine residue of the target by the spatial environment can be a significant influence on the reaction yield is known. The site-specific antibody modification techniques is being developed, in many cases, engineered antibody antibody itself needs to be modified, the modification of functions of the antibody with considering the high cost of development and not necessarily always advantageous.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KAGOSHIMA UNIVERSITY
  • Inventor
  • ITO Yuji
IPC(International Patent Classification)
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close